<DOC>
	<DOCNO>NCT00954278</DOCNO>
	<brief_summary>The purpose study determine number patient advance , relapse non-small cell lung cancer tolerate dose escalation sorafenib 400 mg twice daily either 600 mg twice daily 800 mg twice daily . Safety tolerability sorafenib also examine .</brief_summary>
	<brief_title>Intra-patient Dose Escalation Study Sorafenib Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Non-small cell lung cancer ( NSCLC ) lead cause cancer-related mortality U.S. Time progression advance disease remain poor study new agent novel mechanism action need improve duration quality life NSCLC patient . Sorafenib oral-multi-kinase inhibitor effect tumor proliferation tumor angiogenesis . Sorafenib demonstrate activity preclinical model NSCLC combination chemotherapy monotherapy . A recent intra-patient dose escalation trial sorafenib renal cell carcinoma show positive response rate tolerability 1200mg 91 % patient . This study attempt similar dose-escalation sorafenib NSCLC patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm , advance ( stage IIIB pleural effusion , stage IV , recurrent ) , kras mutation positive , nonsmall cell lung cancer ( NSCLC ) Measurable disease per RECIST criterion Patients must receive one + prior chemotherapy regimen NSCLC Patients may treat clinically stable brain metastasis Adequate bone marrow , liver renal function Women childbearing potential must negative serum pregnancy test within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation , 3 month last administration sorafenib Patients must ability understand willingness sign write informed consent International normalize ratio ( INR ) &lt; 1.5 prothrombin time/ partial thromboplastin time ( PT/PTT ) within normal limit Prior exposure Ras pathway inhibitor Any antitumor therapy within 3 week enrollment Prior bevacizumab within past 6 week An active secondary malignancy except nonmelanoma skin cancer Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina new onset angina myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy Uncontrolled hypertension , define systolic blood pressure &gt; 150mm Hg diastolic pressure &gt; 90mm Hg , despite optical medical management Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C Active clinically serious infection &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event &gt; /= CTCAE Grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; /= CTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer , bone fracture Evidence history bleed diathesis coagulopathy Major surgery , open biopsy significant traumatic injury within 4 week first study drug Use St. John 's Wort rifampin Known suspect allergy sorafenib agent give course trial Any condition impair patient 's ability swallow whole pill Any malabsorption problem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>phase 1</keyword>
	<keyword>sorafenib</keyword>
	<keyword>intrapatient dose escalation</keyword>
</DOC>